RB loss contributes to aggressive tumor phenotypes in MYC-driven triple negative breast cancer

Cell Cycle

Volumn 14, Issue 1, 2015, Pages 109-122

  Knudsen, Erik S ^a   Kathleen McClendon, A ^b   Franco, Jorge ^a   Ertel, Adam ^b   Fortina, Paolo ^b,c   Witkiewicz, Agnieszka K ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Basal like breast cancer; Biomarkers; Cell cycle; EMT; MYC; p53; RB tumor suppressor; Targeted therapy; Triple negative breast cancer

Indexed keywords

4 [4 (1,3 BENZODIOXOL 5 YL) 5 (2 PYRIDINYL) 1H IMIDAZOL 2 YL]BENZAMIDE; DINACICLIB; FLAVOPIRIDOL; MATRIGEL; MYC PROTEIN; PROTEIN P53; RETINOBLASTOMA PROTEIN; UVOMORULIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PHOSPHATIDYLINOSITOL 3 KINASE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BREAST EPITHELIUM CELL; CELL ADHESION; CELL DIFFERENTIATION; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CONTROLLED STUDY; DNA REPLICATION; EPITHELIAL MESENCHYMAL TRANSITION; FLOW CYTOMETRY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PROTEIN DEPLETION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRIPLE NEGATIVE BREAST CANCER; ANIMAL; CELL CULTURE; CELL CULTURE TECHNIQUE; CELL MOTION; CELL PROLIFERATION; CYTOLOGY; DOWN REGULATION; EPITHELIUM CELL; FEMALE; GENETICS; METABOLISM; NUDE MOUSE; PATHOLOGY; PHENOTYPE; UDDER; UPREGULATION;

ANIMALS; CELL CULTURE TECHNIQUES; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; DOWN-REGULATION; EPITHELIAL CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; MAMMARY GLANDS, ANIMAL; MICE; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; PHENOTYPE; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-MYC; RETINOBLASTOMA PROTEIN; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 84929456514     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/15384101.2014.967118     Document Type: Article

References (48)

1. Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490 (7418):61-70; PMID:23000897; http://dx.doi.org/ 10.1038/nature11412
2. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al. Molecular portraits of human breast tumours. Nature 2000; 406(6797):747-752; PMID:10963602; http://dx.doi.org/10.1038/35021093
3. Baselga J. Treatment of HER2-overexpressing breast cancer. Ann Oncol 2010; 21 Suppl 7:vii36-40; PMID: 20943641
4. Prat A, Baselga J. The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2. Nat Clin Pract Oncol 2008; 5(9):531-542; PMID:18607391; http://dx.doi. org/10.1038/ncponc1179
5. Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 2009; 9(9):631-643; PMID:19701242; http://dx. doi.org/10.1038/nrc2713
6. Carey L, Winer E, Viale G, Cameron D, Gianni L. Triple- negative breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol 7(12):683-692; PMID: 20877296; http://dx.doi.org/10.1038/nrclinonc.2010. 154
7. Reis-Filho JS, Tutt AN. Triple negative tumours: a critical review. Histopathology 2008; 52(1):108-118; PMID:18171422; http://dx.doi.org/10.1111/j.1365- 2559.2007.02889.x
8. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011; 121(7):2750-2767; PMID: 21633166
9. Herschkowitz JI, He X, Fan C, Perou CM. The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas. Breast Cancer Res 2008; 10(5):R75; PMID:18782450; http://dx.doi.org/10.1186/bcr2142
10. Soucek L, Evan GI. The ups and downs of Myc biology. Curr Opin Genet Dev 2010; 20(1):91-95; PMID:19962879
11. Xu J, Chen Y, Olopade OI. MYC and Breast Cancer. Genes Cancer 2010; 1(6):629-640; PMID:21779462
12. Conacci-Sorrell M, McFerrin L, Eisenman RN. An Overview of MYC and Its Interactome. Cold Spring Harbor perspectives in Med 2014; 4(1); PMID: 24384812; http://dx.doi.org/10.1101/cshperspect. a014357
13. Alles MC, Gardiner-Garden M, Nott DJ, Wang Y, Foekens JA, Sutherland RL, Musgrove EA, Ormandy CJ. Meta-analysis and gene set enrichment relative to er status reveal elevated activity of MYC and E2F in the "basal" breast cancer subgroup. PLoS One 2009; 4(3): e4710; PMID:19270750; http://dx.doi.org/10.1371/ journal.pone.0004710
14. Lin CY, Loven J, Rahl PB, Paranal RM, Burge CB, Bradner JE, Lee TI, Young RA. Transcriptional amplification in tumor cells with elevated c-Myc. Cell 2012; 151(1):56-67; PMID:23021215; http://dx.doi.org/ 10.1016/j.cell.2012.08.026
15. Cowling VH, Cole MD. E-cadherin repression contributes to c-Myc-induced epithelial cell transformation. Oncogene 2007; 26(24):3582-3586; PMID: 17146437; http://dx.doi.org/10.1038/sj.onc.1210132
16. Evan GI,Wyllie AH, Gilbert CS, Littlewood TD, Land H, Brooks M, Waters CM, Penn LZ, Hancock DC. Induction of apoptosis in fibroblasts by c-myc protein. Cell 1992; 69(1):119-128; PMID:1555236; http://dx. doi.org/10.1016/0092-8674(92)90123-T
17. Leone G, Sears R, Huang E, Rempel R, Nuckolls F, Park CH, Giangrande P, Wu L, Saavedra HI, Field SJ, et al. Myc requires distinct E2F activities to induce S phase and apoptosis. Mol Cell 2001; 8(1):105-113; PMID:11511364; http://dx.doi.org/10.1016/S1097- 2765(01)00275-1
18. Fujiwara K, Yuwanita I, Hollern DP, Andrechek ER. Prediction and genetic demonstration of a role for activator E2Fs in Myc-induced tumors. Cancer Res 2011; 71(5):1924-1932; PMID:21245101; http://dx.doi.org/ 10.1158/0008-5472.CAN-10-2386
19. Xu XL, Fang Y, Lee TC, Forrest D, Gregory-Evans C, AlmeidaD, Liu A, Jhanwar SC, AbramsonDH, Cobrinik D. Retinoblastoma has properties of a cone precursor tumor and depends upon cone-specificMDM2 signaling. Cell 2009; 137(6):1018-1031; PMID:19524506; http:// dx.doi.org/10.1016/j.cell.2009.03.051
20. Dean JL, McClendon AK, Stengel KR, Knudsen ES. Modeling the effect of the RB tumor suppressor on disease progression: dependence on oncogene network and cellular context. Oncogene 29(1):68-80; PMID: 19802012; http://dx.doi.org/10.1038/onc.2009.313
21. Saddic LA, Wirt S, Vogel H, Felsher DW, Sage J. Functional interactions between retinoblastoma and c- MYC in a mouse model of hepatocellular carcinoma. PLoS One 2011; 6(5):e19758; PMID:21573126; http://dx.doi.org/10.1371/journal.pone.0019758
22. Jiang Z, Jones R, Liu JC, Deng T, Robinson T, Chung PE, Wang S, Herschkowitz JI, Egan SE, Perou CM, Zacksenhaus E. RB1 and p53 at the crossroad of EMT and triple-negative breast cancer. Cell Cycle 2011; 10(10):1563-1570; PMID:21502814; http://dx.doi. org/10.4161/cc.10.10.15703
23. Khew-Goodall Y, Goodall GJ. Myc-modulated miR-9 makes more metastases. Nat Cell Biol. 2010; 12 (3):209-211; PMID:20173743
24. Liu M, Casimiro MC, Wang C, Shirley LA, Jiao X, Katiyar S, Ju X, Li Z, Yu Z, Zhou J, et al. p21CIP1 attenuates Ras- and c-Myc-dependent breast tumor epithelial mesenchymal transition and cancer stem cell-like gene expression in vivo. Proc Natl Acad Sci U S A 2009; 106(45):19035-19039; PMID:19858489; http://dx.doi.org/10.1073/pnas.0910009106
25. Jiang Z, Deng T, Jones R, Li H, Herschkowitz JI, Liu JC, Weigman VJ, Tsao MS, Lane TF, Perou CM, Zacksenhaus E. Rb deletion in mouse mammary progenitors induces luminal-B or basal-like/EMT tumor subtypes depending on p53 status. J Clin Invest 2010; 120(9):3296-3309; PMID:20679727; http://dx.doi. org/10.1172/JCI41490
26. Witkiewicz AK, Cox DW, Rivadeneira D, Ertel AE, Fortina P, Schwartz GF, Knudsen ES. The retinoblastoma tumor suppressor pathway modulates the invasiveness of ErbB2-positive breast cancer. Oncogene 2014; 33(30):3980-3991; PMID:24121271
27. Arima Y, Inoue Y, Shibata T, Hayashi H, Nagano O, Saya H, Taya Y. Rb depletion results in deregulation of E-cadherin and induction of cellular phenotypic changes that are characteristic of the epithelial-to-mesenchymal transition. Cancer Res 2008; 68(13):5104- 5112; PMID:18593909; http://dx.doi.org/10.1158/ 0008-5472.CAN-07-5680
28. Arima Y, Hayashi H, Sasaki M, Hosonaga M, Goto TM, Chiyoda T, Kuninaka S, Shibata T, Ohata H, Nakagama H, Taya Y, Saya H. Induction of ZEB proteins by inactivation of RB protein is key determinant of mesenchymal phenotype of breast cancer. J Biol Chem 287(11):7896-7906; PMID:22262832; http:// dx.doi.org/10.1074/jbc.M111.313759
29. Knudsen ES, Wang JY. Targeting the RB-pathway in cancer therapy. Clin Cancer Res 2010; 16(4):1094- 1099; PMID:20145169; http://dx.doi.org/10.1158/ 1078-0432.CCR-09-0787
30. Knudsen ES, Knudsen KE. Tailoring to RB: tumour suppressor status and therapeutic response. Nat Rev Cancer 2008; PMID:19143056
31. Dawson SJ, Provenzano E, Caldas C. Triple negative breast cancers: clinical and prognostic implications. Eur J Cancer 2009; 45 Suppl 1:27-40; PMID:19775602; http://dx.doi.org/10.1016/S0959-8049(09)70013-9
32. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med 2010; 363(20):1938- 1948; PMID:21067385; http://dx.doi.org/10.1056/ NEJMra1001389
33. Knudsen ES, Pajak TF, Qeenan M, McClendon AK, Armon BD, Schwartz GF, Witkiewicz AK. Retinoblastoma and phosphate and tensin homolog tumor suppressors: impact on ductal carcinoma in situ progression. J Natl Cancer Inst 2012; 104(23):1825- 1836; PMID:23197489; http://dx.doi.org/10.1093/ jnci/djs446
34. Witkiewicz AK, Rivadeneira DB, Ertel A, Kline J, Hyslop T, Schwartz GF, Fortina P, Knudsen ES. Association of RB/p16-pathway perturbations with DCIS recurrence: dependence on tumor versus tissue microenvironment. Am J Pathol 2011; 179(3):1171-1178; PMID:21756866; http://dx.doi.org/10.1016/j.ajpath. 2011.05.043
35. Burkhart DL, Sage J. Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat Rev Cancer 2008; 8(9):671-682; PMID:18650841; http://dx. doi.org/10.1038/nrc2399
36. Knudsen ES, Knudsen KE. Retinoblastoma tumor suppressor: where cancer meets the cell cycle. Exp Biol Med (Maywood) 2006; 231(7):1271-1281; PMID: 16816134
37. Chandriani S, Frengen E, Cowling VH, Pendergrass SA, Perou CM, Whitfield ML, Cole MD. A core MYC gene expression signature is prominent in basal-like breast cancer but only partially overlaps the core serum response. PLoS One 2009; 4(8):e6693; PMID:19690609; http://dx.doi.org/10.1371/journal. pone.0006693
38. Markey MP, Bergseid J, Bosco EE, Stengel K, Xu H, Mayhew CN, Schwemberger SJ, Braden WA, Jiang Y, Babcock GF, et al. Loss of the retinoblastoma tumor suppressor: differential action on transcriptional programs related to cell cycle control and immune function. Oncogene 2007; 26(43):6307-6318; PMID: 17452985; http://dx.doi.org/10.1038/sj.onc.1210450
39. Robinson TJ, Liu JC, Vizeacoumar F, Sun T, Maclean N, Egan SE, Schimmer AD, Datti A, Zacksenhaus E. RB1 status in triple negative breast cancer cells dictates response to radiation treatment and selective therapeutic drugs. PLoS One 2013; 8(11):e78641; http://dx. doi.org/10.1371/journal.pone.0078641
40. Bosco EE, Wang Y, Xu H, Zilfou JT, Knudsen KE, Aronow BJ, Lowe SW, Knudsen ES. The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer. J Clin Invest 2007; 117 (1):218-228; PMID:17160137; http://dx.doi.org/ 10.1172/JCI28803
41. Derenzini M, Donati G, Mazzini G, Montanaro L, Vici M, Ceccarelli C, Santini D, Taffurelli M, Trere D. Loss of retinoblastoma tumor suppressor protein makes human breast cancer cells more sensitive to antimetabolite exposure. Clin Cancer Res 2008; 14(7):2199-2209; PMID:18381962; http://dx.doi.org/10.1158/1078- 0432.CCR-07-2065
42. Ertel A, Dean JL, Rui H, Liu C,Witkiewicz AK, Knudsen KE, Knudsen ES. RB-pathway disruption in breast cancer: differential association with disease subtypes, disease-specific prognosis and therapeutic response. Cell Cycle 9(20):4153-4163; PMID:20948315; http:// dx.doi.org/10.4161/cc.9.20.13454
43. Witkiewicz AK, Ertel A, McFalls JM, Valsecchi ME, Schwartz G, Knudsen ES. RB-pathway Disruption is Associated with Improved Response to Neoadjuvant Chemotherapy in Breast Cancer. Clin Cancer Res.
44. McClendon AK, Dean JL, Ertel A, Fu Z, Rivadeneira DB, Reed CA, Bourgo RJ, Witkiewicz A, Addya S, Mayhew CN, Grimes HL, Fortina P, Knudsen ES. RB and p53 cooperate to prevent liver tumorigenesis in response to tissue damage. Gastroenterology 2011; 141 (4):1439-1450; PMID:21704587; http://dx.doi.org/ 10.1053/j.gastro.2011.06.046
45. Knudsen KE, Booth D, Naderi S, Sever-Chroneos Z, Fribourg AF, Hunton IC, Feramisco JR, Wang JY, Knudsen ES. RB-dependent S-phase response to DNA damage. Mol Cell Biol 2000; 20(20):7751-7763; PMID:11003670; http://dx.doi.org/10.1128/ MCB.20.20.7751-7763.2000
46. Bourgo RJ, Thangavel C, Ertel A, Bergseid J,McClendon AK, Wilkens L, Witkiewicz AK, Wang JY, Knudsen ES. RB restricts DNA damage-initiated tumorigenesis through an LXCXE-dependent mechanism of transcriptional control. Mol Cell 2011; 43(4):663-672; PMID:21855804; http://dx.doi.org/10.1016/j.molcel.2011.06.029
47. Witkiewicz AK, Dasgupta A, Sotgia F, Mercier I, Pestell RG, Sabel M, Kleer CG, Brody JR, Lisanti MP. An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers. Am J Pathol 2009; 174(6):2023-2034; PMID:19411448; http://dx.doi.org/10.2353/ ajpath.2009.080873
48. Johnson NA, Slack GW, Savage KJ, Connors JM, Ben- Neriah S, Rogic S, Scott DW, Tan KL, Steidl C, Sehn LH, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 2012; 30(28):3452-3459; PMID:22851565; http://dx.doi.org/10.1200/JCO. 2011.41.0985